RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Stock-based compensation

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.6B
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 2024272+22.74%
Dec 31, 2023222-3.89%
Dec 31, 2022231+39.18%
Dec 31, 2021166+18.48%
Dec 31, 2020140-20.00%
Dec 31, 2019175+10.83%
Dec 31, 2018158+69.96%
Dec 31, 201793+22.89%
Dec 31, 201676+64.97%
Dec 31, 201546+38.48%
Dec 31, 201433+59.69%
Dec 31, 201321+67.50%
Dec 31, 201212-25.88%
Dec 31, 201117-12.77%
Dec 31, 201019

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)